Breaking News

GSK, Regulus Therapeutics Form MicroRNA Alliance

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Regulus Therapeutics have entered into a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus is a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals.     The alliance leverages Regulus’ expertise and intellectual property in the discovery and development of microRNA-targeted therapeutics and provides GSK with...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters